Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.50 +0.52 (+1.08%)
Streaming Delayed Price Updated: 12:18 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase. 
Via InvestorPlace
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Via Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
The company is working on protein degradation in cancer and inflammatory diseases. 
Via Investor's Business Daily
Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal
HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies. 
Via InvestorPlace
Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal
The deal comes a day after Sanofi dropped out of the bidding process. 
Via Investor's Business Daily
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union. 
Via The Motley Fool
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
Via Benzinga
This Monster Dividend Stock Isn't Done Growing
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Via Benzinga
Fusion Fuel (HTOO) Stock Is Up 11% on HUGE Deal News
Fusion Fuel (HTOO) stock is heading higher on Wednesday after the company secured a deal with the Portuguese government. 
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
TransCode Therapeutics (RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. 
Via InvestorPlace
SNY Stock Alert: Why 1 Analyst Says Zantac Ruling Is ‘Best-Case Scenario’ for Drugmakers
Sanofi (SNY) stock is in the news as one analyst believes the latest court ruling is the "best-case scenario" for the drugmaker. 
Via InvestorPlace
Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07
Benzinga 
Via Benzinga
Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac
Via Benzinga
These 3 Stocks Escaped Tuesday's Market Downdraft
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies. 
Via The Motley Fool
Why GSK Plc And Sanofi SA Stock Are Shooting Higher
Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit. 
Via Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash
Via Benzinga
Why Horizon Therapeutics Stock Is Skyrocketing Today
Three big drugmakers could be interested in acquiring Horizon. 
Via The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout. 
Via InvestorPlace
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Tech layoffs are in the news, but life sciences companies seem to be doing better. 
Via The Motley Fool
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
Via Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Reuters 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.